United Therapeutics (UTHR) Gross Margin (2009 - 2026)

United Therapeutics has disclosed Gross Margin across 18 years of filings, most recently posting 82.93% for Q1 2026.

• Gross Margin for Q1 2026 came in at 82.93%, down 543.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 86.58% (down 242.0% YoY), and the FY2025 annual result was 87.92%, down 131.0% from the prior year.
• Gross Margin came in at 82.93% for Q1 2026 at United Therapeutics, down from 86.91% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 94.39% in Q1 2022 to a low of 82.93% in Q1 2026.
• The 5-year median for Gross Margin is 89.03% (2025), against an average of 89.19%.
• Across the five-year window, Gross Margin soared 197 bps in 2022 and tumbled 543 bps in 2026, its largest moves.
• United Therapeutics' Gross Margin stood at 88.04% in 2022, then advanced by 0 bps to 88.45% in 2023, then increased by 1 bps to 89.69% in 2024, then retreated by 3 bps to 86.91% in 2025, then retreated by 5 bps to 82.93% in 2026.
• The last three Gross Margin figures came in at 82.93% (Q1 2026), 86.91% (Q4 2025), and 87.38% (Q3 2025), per Business Quant data.